[Meta analysis of rock salt aerosol therapy for respiratory tract diseases].

Objective: To systematically evaluate the efficacy and safety of rock salt aerosol in the treatment of respiratory tract diseases. Methods: In June 2021, the clinical randomized controlled trial literatures of rock salt aerosol therapy for respiratory tract diseases were searched from CNKI, Wanfang, VIP, Cochrane Library, PubMed database and EMBASE database. Cochrane risk bias evaluation tool was used to evaluate risk bias, Revman 5.4 and Stata16 were used to conduct meta-analysis, TSA 0.9 was used to conduct sequential analysis of trials, and gradepro was used to evaluate evidence quality. Results: A total of 21 literatures were included. According to whether the subjects received rock salt aerosol therapy, they were divided into the experimental group (1125 people) and the control group (973 people) . Compared with the control group, the total clinical effective rate (RR=1.22, 95%CI: 1.15~1.29, P<0.001) , forced expiratory volume in one second (FEV(1)) (WMD=0.20, 95%CI: 0.09~0.31, P<0.001) , percentage of FEV(1) in the predicted value (FEV(1)%) (WMD=5.06, 95%CI: 3.47~6.65, P<0.001) , forced vital capacity (FVC) (WMD=0.22, 95% CI: 0.16~0.27, P<0.001) , maximum expiratory flow (PEF) (WMD=21.312, 95%CI: 9.189~33.435, P=0.004) of experimental group were higher. TSA test shows that the difference conclusions of total effective rate, FEV(1), FEV(1)%, FVC and PEF were reliable, but the conclusion of FEV(1)% needs to be treated with caution; Three literatures reported the adverse reactions in the experimental group; GRADE evidence quality evaluation showed 3 very low-quality evidences and 2 low-quality evidences. Conclusion: Rock salt aerosol therapy combined with conventional therapy has a certain effect on the treatment of respiratory tract diseases, which needs to be further confirmed by high-quality evidence.目的： 系统评价岩盐气溶胶疗法治疗呼吸道疾病的效果及安全性。 方法： 于2021年6月，通过中国知网（CNKI）、万方数据知识服务平台（wanfang）、维普中文期刊（VIP）、Cochrane library、PubMed数据库、Embase数据库中检索岩盐气溶胶疗法治疗呼吸道疾病的临床随机对照试验文献，应用Cochrane风险偏倚评估工具进行风险偏倚评价，应用Revman 5.4和Stata 16软件进行meta分析，应用TSA 0.9进行试验序贯分析，GRADEpro软件进行证据质量评价。 结果： 共纳入21篇文献，根据研究对象是否接受了岩盐气溶胶疗法分为试验组（1 125人）和对照组（973人）。与对照组比较，试验组临床总有效率（RR=1.22，95%CI：1.15~1.29，P<0.001），1秒用力呼气容积（FEV(1)）（WMD=0.20，95%CI：0.09~0.31，P<0.001），FEV(1)占预测值百分比（FEV(1)%）（WMD=5.06，95%CI：3.47~6.65，P<0.001），用力肺活量（FVC）（WMD=0.22，95%CI：0.16~0.27，P<0.001），最大呼气流量（PEF）（WMD=21.312，95%CI：9.189~33.435，P=0.004）均有所提高。TSA检验显示总有效率、FEV(1)、FEV(1)%、FVC、PEF的差异性结论可信，但对于FEV(1)%的结论需要谨慎对待；有3篇文献报告了试验组不良反应情况；GRADE证据质量评价显示3条极低质量证据，2条低质量证据。 结论： 岩盐气溶胶疗法联合常规疗法治疗呼吸道疾病有一定效果，需高质量证据进一步确证。.